Addex’s Kalinichev reports ADXN share and option stake

Addex Therapeutics Ltd. executive Mikhail Kalinichev filed an initial ownership report showing his equity stake in the company.

Rhea-AI Filing Summary

Addex Therapeutics Ltd. executive Mikhail Kalinichev filed an initial ownership report showing his equity stake in the company. He directly holds 306,765 shares of Common Stock listed on SIX Swiss Exchange and a stock option covering 200,000 shares at an exercise price of $0.0640 per share. The option is exercisable from August 1, 2024, vests in equal monthly installments over four years, and expires on January 7, 2034. Each option entitles him to purchase one ADXN share on SIX Swiss Exchange.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Kalinichev Mikhail

Role HEAD OF TRANSLATIONAL SCIENCE

Type	Security	Shares	Price	Value
holding	Stock-Option (Right to Buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock-Option (Right to Buy) — 200,000 contracts (Direct); Common Stock — 306,765 shares (Direct)

Footnotes (3)

1. F1. Represents 306,765 shares of Common Stock listed on SIX Swiss Exchange.
2. F2. The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange.
3. F3. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.2769 per CHF 1.00 as of March 12, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider position did Kalinichev report in Addex Therapeutics (ADXN)?

Mikhail Kalinichev reported holding 306,765 shares of Addex Therapeutics Common Stock. He also reported a stock option over 200,000 shares, giving him additional potential equity exposure if he chooses to exercise those options in the future.

How many Addex Therapeutics (ADXN) stock options does Kalinichev hold?

He holds a stock option covering 200,000 shares of Addex Therapeutics Common Stock. The option vests in equal monthly installments over four years, providing a long-term incentive tied to the company’s share performance on SIX Swiss Exchange.

What is the exercise price and schedule of Kalinichev’s ADXN stock options?

The stock option has an exercise price of $0.0640 per share, translated from CHF. It becomes exercisable from August 1, 2024 and vests in equal monthly installments over four years, aligning compensation with sustained company performance.

When do Kalinichev’s Addex Therapeutics stock options expire?

Kalinichev’s stock option position in Addex Therapeutics expires on January 7, 2034. This long-dated expiry gives him a lengthy window to decide if and when to exercise up to 200,000 shares based on future company and market conditions.

On which exchange are Kalinichev’s Addex Therapeutics shares listed?

The 306,765 shares of Common Stock reported by Kalinichev are listed on SIX Swiss Exchange. Each stock option he holds also grants the right to purchase one ADXN share traded on the same Swiss exchange, according to the filing footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/25/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kalinichev Mikhail

(Last) (First) (Middle)

CHEMIN DES MINES 9

(Street)

GENEVA CH-1202

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Addex Therapeutics Ltd. [ ADXN ]

3a. Foreign Trading Symbol
[ADXN]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	HEAD OF TRANSLATIONAL SCIENCE

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	306,765(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock-Option (Right to Buy)	08/01/2024(2)	01/07/2034	Common Stock	200,000	$0.064(3)	D

Explanation of Responses:

1. Represents 306,765 shares of Common Stock listed on SIX Swiss Exchange.

2. The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange.

3. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.2769 per CHF 1.00 as of March 12, 2026.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Lenaic Nathanael Teyssedou by power of attorney	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)